A small randomised trial finding that weight loss reduced IL-1β and MASLD comparably with liraglutide or lifestyle, and that baseline IL-1β predicted the extent of MASLD improvement. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A multicentre randomised trial found dapagliflozin 10 mg daily for 48 weeks improved biopsy-confirmed MASH without worsening fibrosis in more patients than placebo. PICO summary and expert commentary.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.